drugset / Trial / NCT03522142
A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and early clinical activity of single-agent INCB081776 (Part 1) and INCB081776 in combination with INCMGA00012 (Part 2).
Timeline
- Start
- 2018-08-27
- Primary completion
- 2025-09-10
- Completion
- 2025-09-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | INCB081776 | Unknown | — | Oral |
| Subject | Retifanlimab | Monoclonal antibody | 500 mg | Intravenous |